Show simple item record

dc.contributor.authorChampiat, S.en
dc.contributor.authorBoyer, M. J.en
dc.contributor.authorGovindan, R.en
dc.contributor.authorPaz-Ares, L. G.en
dc.contributor.authorOwonikoko, T. K.en
dc.contributor.authorBorghaei, H.en
dc.contributor.authorIzumi, H.en
dc.contributor.authorSteeghs, N.en
dc.contributor.authorBlackhall, Fiona Hen
dc.contributor.authorTerbuch, A.en
dc.contributor.authorJohnson, M. L.en
dc.contributor.authorYoshida, T.en
dc.contributor.authorHe, K.en
dc.contributor.authorZhang, Y. Y.en
dc.contributor.authorJones, S.en
dc.contributor.authorChen, X.en
dc.contributor.authorMartinez, P.en
dc.contributor.authorHummel, H. D.en
dc.date.accessioned2023-10-25T08:48:37Z
dc.date.available2023-10-25T08:48:37Z
dc.date.issued2023en
dc.identifier.citationChampiat S, Boyer MJ, Govindan R, Paz-Ares LG, Owonikoko TK, Borghaei H, et al. Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003656.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.8582en
dc.identifier.urihttp://hdl.handle.net/10541/626654
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.8582en
dc.titleTarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasisen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGustave Roussy, Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Villejuif, Franceen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record